Thrombolytic or 'clot busting' drugs
Thrombolytic or "clot-busting" drugs offer an emergency treatment option for some people who are having a stroke. These medications, which include an agent called a tissue plasminogen activator (t-PA), halt the stroke by dissolving the blood clot that is blocking blood flow to the brain.
Recombinant tissue plasminogen activator (rt-PA) is a genetically engineered form of t-PA. This drug only works if it is given intravenously within three hours of the onset of stroke symptoms. It poses risks to patients who are taking blood-thinners or who have recently undergone surgery or trauma.
Providence Stroke Center is currently comparing different methods of giving t-PA to stroke patients, with the goal of extending the window of time during which the drug can be given and making the treatment safer for more patients.
Current research includes comparing the safety and effectiveness of administering t-PA with a catheter or with a combination of catheter and IV. Read a physician-level summary of this research to date.
Questions? Please call: 503-216-2346
Providence Stroke Center is the first nationally certified primary stroke center in Oregon and a leader in accessible, comprehensive, state-of-the-art stroke care, education and research, Providence Stroke Center cares for more stroke patients than any other health system in Oregon.